BTX BioTime Inc.

2.83
-0.02  -1%
Previous Close 2.85
Open 2.88
Price To book 1.86
Market Cap 327725467
Shares 115,804,052
Volume 233,552
Short Ratio 23.49
Av. Daily Volume 289,497

SEC filingsSee all SEC filings

  1. CT ORDER - Confidential treatment order 171075695
  2. 8-K - Current report 171077971
  3. 8-K - Current report 171037625
  4. 8-K/A [Amend] - Current report 171031526
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 171018890

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 six and nine-month data released January 24, 2017. 10 and 20m cell cohort 6-month top-line data due January 2018. Cohort 2 12-month data due later in 2017.
AST-OPC1 - SCiStar
Cervical spinal cord injury
Pivotal trial data released June 14, 2017 - primary endpoint met.
Renevia
Restoring normal skin contours in for patients with HIV
Phase 2 second cohort underway. Interim data presented at May 8, 2017 at ARVO conference. Third cohort enrollment to commence in the coming weeks, as of July 25, 2017, following green light from DSMB.
OpRegen
Dry age-related macular degeneration (AMD)
Phase 2b planned for 2018.
AST-VAC1
Maintenance of relapse-free-survival in acute myeloid leukemia (AML)

Latest News

  1. BioTime Awarded Grant from the NIH
  2. Two Key BioTime Patents Providing Protection to OpRegen® Remain Upheld
  3. ETFs with exposure to BioTime, Inc. : September 12, 2017
  4. BioTime, Inc. :BTX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 9, 2017
  5. BioTime to Present at the Rodman & Renshaw Annual Global Investment Conference
  6. BioTime to Present at the LD Micro San Francisco Summit
  7. BioTime, Inc. breached its 50 day moving average in a Bullish Manner : BTX-US : September 1, 2017
  8. BioTime to Present Data at the Military Health System Research Symposium
  9. AgeX Therapeutics Closes $10 Million Capital Raise
  10. BioTime Announces $2 Million Grant for Further Development of OpRegen® for Dry-AMD
  11. Edited Transcript of BTX earnings conference call or presentation 2-Aug-17 8:30pm GMT
  12. AgeX Therapeutics CEO Michael D. West, Ph.D. to Deliver Keynote Address on Biotechnology and Aging at RAAD Festival
  13. BioTime reports 2Q loss
  14. BioTime Reports Second Quarter Results and Recent Corporate Accomplishments
  15. Investor Network: BIOTIME INC to Host Earnings Call
  16. AgeX Therapeutics Obtains $10 Million in Capital and Commences Operations
  17. BioTime, Inc. – Value Analysis (NYSE MKT:BTX) : July 31, 2017
  18. BioTime Receives DSMB Approval to Start Third Patient Cohort in Clinical Trial for Dry-AMD; Commences Patient Enrollment in the US
  19. BioTime, Inc. to Announce Second Quarter 2017 Results on August 2, 2017
  20. Data From BioTime’s Phase I/IIa OpRegen® Trial to be Presented at the 2017 American Academy of Ophthalmology (AAO) Annual Meeting

SEC Filings

  1. CT ORDER - Confidential treatment order 171075695
  2. 8-K - Current report 171077971
  3. 8-K - Current report 171037625
  4. 8-K/A [Amend] - Current report 171031526
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 171018890
  6. 8-K - Current report 171001283
  7. DEFR14A - Revised definitive proxy soliciting materials 17964178
  8. S-8 - Securities to be offered to employees in employee benefit plans 17955946
  9. 8-K - Current report 17952690
  10. PRER14A - Preliminary Proxy Soliciting materials 17943248